4Mallat Z, Heymes C, Corbaz A, et al. Evidence for altered interleukin 18(IL-18) pathway in human heart failure. FASEB J, 2004,18 : 1752-1754.
5Chandrasekar B, Mummidi S, Claycomb WC, et al. Interleukin- 18 is a pro hypertrophic cytokine that acts through a phosphatidylinositol 3-kinase-phosphoinositide-dependent kinase-1- Akt-GATA4 signaling pathway in cardiomyocytes. J Biol Chem, 2005,280 : 4553-4567.
6Alfieri AB, Briceno L, Fragass OG, et al. Differential ling-term effects of carvedilol on proinflammatory and antiinflammatory cytokines, asymmetric dimethylarginine, and left ventrieular function in patients with heart failure. J Cardiovasc Pharmacol, 2008,52..49-54.
7Yamaoka-Tojo M, Tojo T, Inomata T, et al. Circulating levels of interleukin 18 reflect etiologies of heart failure: Thl/Th2 cytokine imbalance exaggerates the pathophysiology of advanced heart failure. J Card Fail, 2002,8 : 21-27.
8Naito Y, Tsujino T, Fujioka Y, et al. Increased circulating interleukin-18 in patients with congestive heart failure. Heart, 2002,88:296-297.
10[3]Rector TS, Kubo SH, Cohn JN. Patients self-assessment of their congestive heart failure: content, reliability and validity of a new measure, the Minnesota living with heart failure questionnaire [J]. Heart Failure, 1987, 3: 198-209.
